SLC6A4 variation and citalopram response
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The influence of genetic variations in SLC6A4 (serotonin transporter gene) on citalopram treatment of depression using the Sequenced Treatment to Relieve Depression (STAR*D) sample was assessed. Of primary interest were three previously studied polymorphisms: 1) the VNTR variation of the second intron, 2) the indel promoter polymorphism (5HTTLPR or SERT), and 3) a single nucleotide polymorphism (SNP) rs25531. Additionally, SLC6A4 was resequenced to identify new SNPs for exploratory analyses. DNA from 1914 subjects in the STAR*D study were genotyped for the intron 2 VNTR region, the indel promoter polymorphism, and rs25531. Associations of these variants with remission of depressive symptoms were evaluated following citalopram treatment. In white non‐Hispanic subjects, variations in the intron 2 VNTR (point‐wise P = 0.041) and the indel promoter polymorphism (point‐wise P = 0.039) were associated with remission following treatment with citalopram. The haplotype composed of the three candidate loci was also associated with remission, with a global p‐value of 0.040 and a maximum statistic simulation p‐value of 0.0031 for the S‐a‐12 haplotype, under a dominant model. One SNP identified through re‐sequencing the SLC6A4 gene, Intron7‐83‐TC, showed point‐wise evidence of association, which did not remain significant after correction for the number of SNPs evaluated in this exploratory analysis. No associations between these SLC6A4 variations and remission were found in the white Hispanic or black subjects. These findings suggest that multiple variations in the SLC6A4 gene are associated with remission in white non‐Hispanic depressed adults treated with citalopram. The mechanism of action of these variants remains to be determined. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 2×
“…summary, all participants provided written informed consent, were between 18 and 75 years of age and met DSM-IV criteria for non-psychotic MDD. Symptomatic status was measured using the QIDS-C16, which rates all nine criterion symptom domains of MDD [Rush et al., 2003, 2006; Trivedi et al., 2004].”
MethodSelf-citationSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968 · cited 2×
“…summary, all participants provided written informed consent, were between 18 and 75 years of age and met DSM-IV criteria for non-psychotic MDD. Symptomatic status was measured using the QIDS-C16, which rates all nine criterion symptom domains of MDD [Rush et al., 2003, 2006; Trivedi et al., 2004].”
MethodSelf-citationSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529 · cited 2×
“Variations in the promoter region of SLC6A4 (serotonin transporter gene) have been reported to be associated with differential remission rates following selective serotonin reuptake inhibitor (SSRI) medication treatment [Serretti and Artioli, 2004; Serretti et al., 2007].”
BackgroundResultInfluentialRush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385 · cited 3×
“Previous papers have documented differences between the subjects who contributed DNA and those who did not [Rush et al., 2006].”
MethodResultSelf-citationThase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Cited by
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
“…the s/s one (OR=1.37, C.I. 95% 1.09–1.72, p=0.007 for all antidepressant classes, OR=1.48, C.I. 95% 1.12–1.96, p=0.005 for SSRIs only and including Mrazek et al. (2009)) as well as when we considered together l/l and l/s genotypes versus the s/s genotype (OR=1.28, C.I. 95% 1.02–1.61, p=0.04 for…”
BackgroundMethodResultInfluentialPersonalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Sex, Receptors, and Attachment: A Review of Individual Factors Influencing Response to Oxytocin
MacDonald, K. S. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00194 · Cited by 119
“…(Munafo et al., 2008) and response to dopaminergic medication (Hamarman et al., 2004), or the association of serotonin receptor polymorphisms with susceptibility to adverse clinical outcomes (van Ijzendoorn et al., 2012), as well as response to serotonergic antidepressants (Mrazek et al., 2009).”
BackgroundPharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results
Laje, G., Perlis, R. H., Rush, A. J., & McMahon, F. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1446 · Cited by 89
Self-citationPharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6
Metadata
- Authors
- Mrazek, D. A., Rush, A. J., Biernacka, J. M., O'Kane, D. J., Cunningham, J. M., Wieben, E. D., Schaid, D. J., Drews, M. S., Courson, V. L., Snyder, K. A., Black, J. L., & Weinshilboum, R. M.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2008-07-10
- Volume
- 150B
- Issue
- 3
- Pages
- 341-351
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2096991502
- Cited by
- 136
- References
- 8
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.